注册号: Registration number: |
ChiCTR2000029851 |
最近更新日期: Date of Last Refreshed on: |
2020-02-24 |
注册时间: Date of Registration: |
2020-02-15 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
注册题目: |
硫辛酸注射液在新型冠状病毒肺炎(COVID-19)重型及危重型患者中的有效性及安全性的多中心、随机对照临床研究 |
Public title: |
A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19) |
注册题目简写: |
|
English Acronym: |
|
研究课题的正式科学名称: |
硫辛酸注射液在新型冠状病毒肺炎(COVID-19)重型及危重型患者中的有效性及安全性的多中心、随机对照临床研究 |
Scientific title: |
A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19) |
研究课题代号(代码): Study subject ID: |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
申请注册联系人: |
徐磊 |
研究负责人: |
葛均波 |
Applicant: |
Lei Xu |
Study leader: |
Junbo Ge |
申请注册联系人电话: Applicant telephone: |
+86 13917731869 |
研究负责人电话: Study leader's telephone: |
+86-21-64041990 |
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
申请注册联系人电子邮件: Applicant E-mail: |
xu.lei2@zs-hospital.sh.cn |
研究负责人电子邮件: Study leader's E-mail: |
jbge@zs-hospital.sh.cn |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
上海市徐汇区枫林路180号 |
研究负责人通讯地址: |
上海市徐汇区枫林路180号 |
Applicant address: |
180 Fenglin Road, Xuhui District, Shanghai, China |
Study leader's address: |
180 Fenglin Road, Xuhui District, Shanghai, China |
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
申请人所在单位: |
复旦大学附属中山医院 |
||
Applicant's institution: |
Zhongshan Hospital, Fudan University |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
B2020-030 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
批准本研究的伦理委员会名称: |
复旦大学附属中山医院伦理委员会 |
||
Name of the ethic committee: |
Ethics Committee of Zhongshan Hospital, Fudan University |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2020-02-17 | ||
伦理委员会联系人: |
杨梦婕 |
||
Contact Name of the ethic committee: |
Mengjie Yang |
||
伦理委员会联系地址: |
上海市徐汇区枫林路180号 |
||
Contact Address of the ethic committee: |
180 Fenglin Road, Xuhui District, Shanghai, China |
||
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
研究实施负责(组长)单位: |
复旦大学附属中山医院 |
||||||||||||||||||||||
Primary sponsor: |
Zhongshan Hospital, Fudan University |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
上海市徐汇区枫林路180号 |
||||||||||||||||||||||
Primary sponsor's address: |
180 Fenglin Road, Xuhui District, Shanghai, China |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
复旦大学 |
||||||||||||||||||||||
Source(s) of funding: |
Fudan University |
||||||||||||||||||||||
研究疾病: |
新型冠状病毒肺炎(COVID-19) |
||||||||||||||||||||||
Target disease: |
Novel Coronavirus Pneumonia (COVID-19) |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
干预性研究 |
||||||||||||||||||||||
Study type: |
Interventional study |
||||||||||||||||||||||
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
Study phase: |
4 |
||||||||||||||||||||||
研究目的: |
评估硫辛酸注射液治疗重型及危重型新型冠状病毒肺炎患者的有效性和安全性 |
||||||||||||||||||||||
Objectives of Study: |
To evaluate the clinical efficacy and safety of Alpha lipoic acid (ALA) for severe patients with 2019 novel coronavirus pneumonia (COVID-19) through randomized controlled trials during the current epidemic of NCP. |
||||||||||||||||||||||
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
研究设计: |
随机平行对照 |
||||||||||||||||||||||
Study design: |
Parallel |
||||||||||||||||||||||
纳入标准: |
(1) 确诊新型冠状病毒肺炎的重症患者及危重症患者; (2) 35岁≤年龄<75岁 (3) 患者及家属自愿参与本项研究并签署知情同意书。 注:病例定义:重症NCP:参考国家卫健委制定《新型冠状病毒肺炎诊疗方案(第五版)》。 |
||||||||||||||||||||||
Inclusion criteria |
1. Severe patients diagnosed with novel coronavirus pneumonia (COVID-19); 2. Aged 35 years old to 74 years old; 3. Patients or authorized family members volunteered to participate in this study and signed informed consent. Note: Case definition: Severe NCP: Refer to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)" formulated by the National Health Commission. |
||||||||||||||||||||||
排除标准: |
(1) 正在参加其他药物临床试验患者; (2) 孕妇或哺乳期的女性; (3) 存在其他可能威胁生命的严重疾病,如癌症; (4) 预期生存期<24小时; (5) 对硫辛酸或相似药物(B族维生素类)过敏患者,既往应用硫辛酸推荐剂量不耐受患者; (6) 有免疫系统疾病或与免疫系统密切相关的疾病史。 |
||||||||||||||||||||||
Exclusion criteria: |
1. Involving in other drug clinical trial; 2. Pregnant or breastfeeding; 3. Presence of other serious diseases that may be life threatening, such as cancer; 4. Expected life is less than 24 hours; 5. Allergy to ALA or drugs of similar chemical classes (Vitamin B),previous history of intolerance to recommended target doses of alpha-LA; 6. diagnosed with diseases of immune system. |
研究实施时间: Study execute time: |
从From2020-02-19至To 2020-03-10 |
征募观察对象时间: Recruiting time: |
从From2020-02-19至To 2020-03-05 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|